KANJINTI

Amgen Canada Inc🇨🇦 Health Canada

Approval Id: 4f9614785296a7a6
Drug Approval Canada Name: KANJINTI
Product Name: KANJINTI
Status: Marketed
Status Date: 2021-10-07
Original Market Date: 2021-10-07
Din: 02518244
Drug Class: Human
Dosage Form: Powder For Solution
Route Of Administration: Intravenous
Schedule: Prescription , Schedule D
Ahfs: 10:00.00
Atc Original: L01FD01 TRASTUZUMAB
Atc Name: l 01 fd 01
Aig Number: 0154252002
Company Name: Amgen Canada Inc
Company Address: 300, 6775 Financial Drive, Mississauga, Ontario, Canada, L5N 0A4

TRASTUZUMAB

150 MG / VIAL

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

4f9614785296a7a6

Type

Standard